and recommendation
BioTime, Inc. (BTX)
BioTime (NYSEMKT: BTX), a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.
BTX’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.
BTX also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products.
Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia.
BioTime, Inc. was founded in 1990 and is based in Alameda, California.
- November 4, 2014 - 9:27am | Regulatory
- November 3, 2014 - 9:44am | Regulatory
- October 16, 2014 - 2:13pm | Earnings Q3
- October 9, 2014 - 10:42am | BOD & C-Suite Updates
- October 6, 2014 - 11:29am | BOD & C-Suite Updates
- October 6, 2014 - 9:48am | Financings
- October 3, 2014 - 10:01am | Research Notes
- September 29, 2014 - 3:06pm
- September 17, 2014 - 9:31am | Research Notes
- September 15, 2014 - 9:40am | Research Notes
- September 8, 2014 - 3:18pm | Model Portfolio
- August 28, 2014 - 10:20am | Regulatory
- August 28, 2014 - 9:55am | Research Notes
- August 21, 2014 - 9:08am | BOD & C-Suite Updates
- August 18, 2014 - 1:35pm | Earnings
- August 12, 2014 - 10:47am | Regulatory
- August 3, 2014 - 10:30pm | Earnings Q2
- July 31, 2014 - 10:38am | Research Notes
- July 25, 2014 - 12:17pm | BOD & C-Suite Updates
- July 25, 2014 - 10:09am | Out and About